{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T13:46:51Z","timestamp":1777038411904,"version":"3.51.4"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Equilibrative nucleoside transporters (ENTs) play a vital role in nucleotide synthesis, regulation of adenosine function and chemotherapy. Current inhibitors of ENTs are mostly ENT1-selective. Our previous study has demonstrated that 4-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-6-imino-N-(naphthalen-2-yl)-1,3,5-triazin-2-amine (FPMINT) is a novel inhibitor of ENTs, which is more selective to ENT2 than to ENT1. The present study aimed to screen a series of FPMINT analogues and study their structure-activity relationship. Nucleoside transporter-deficient cells transfected with cloned human ENT1 and ENT2 were used as <jats:italic>in vitro<\/jats:italic> models. The results of the [<jats:sup>3<\/jats:sup>H]uridine uptake study showed that the replacement of the naphthalene moiety with the benzene moiety could abolish the inhibitory effects on ENT1 and ENT2. The addition of chloride to the meta position of this benzene moiety could restore only the inhibitory effect on ENT1 but had no effect on ENT2. However, the addition of the methyl group to the meta position or the ethyl or oxymethyl group to the para position of this benzene moiety could regain the inhibitory activity on both ENT1 and ENT2. The presence of a halogen substitute, regardless of the position, in the fluorophenyl moiety next to the piperazine ring was essential for the inhibitory effects on ENT1 and ENT2. Among the analogues tested, compound <jats:bold>3c<\/jats:bold> was the most potent inhibitor. Compound <jats:bold>3c<\/jats:bold> reduced <jats:italic>V<\/jats:italic><jats:sub>max<\/jats:sub> of [<jats:sup>3<\/jats:sup>H]uridine uptake in ENT1 and ENT2 without affecting <jats:italic>K<\/jats:italic><jats:sub>m<\/jats:sub>. The inhibitory effect of compound <jats:bold>3c<\/jats:bold> could not be washed out. Compound <jats:bold>3c<\/jats:bold> did not affect cell viability, protein expression and internalization of ENT1 and ENT2. Therefore, similar to FPMINT, compound <jats:bold>3c<\/jats:bold> was an irreversible and non-competitive inhibitor. Molecular docking analysis also showed that the binding site of compound <jats:bold>3c<\/jats:bold> in ENT1 may be different from that of other conventional inhibitors. It is expected that structural modification may further improve its potency and selectivity and lead to the development of useful pharmacological agents.<\/jats:p>","DOI":"10.3389\/fphar.2022.837555","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T11:12:09Z","timestamp":1645441929000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Structure-Activity Relationship Studies of 4-((4-(2-fluorophenyl)piperazin-1-yl)methyl)-6-imino-N-(naphthalen-2-yl)-1,3,5-triazin-2-amine (FPMINT) Analogues as Inhibitors of Human Equilibrative Nucleoside Transporters"],"prefix":"10.3389","volume":"13","author":[{"given":"Renkai","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winston Wing-Shum","family":"Mak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengwen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Polly Ho-Ting","family":"Shiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai-Wang","family":"Seto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon Ming-Yuen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George Pak-Heng","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s00424-003-1103-2","article-title":"The Equilibrative Nucleoside Transporter Family, SLC29","volume":"447","author":"Baldwin","year":"2004","journal-title":"Pflugers Arch."},{"key":"B2","doi-asserted-by":"publisher","first-page":"15880","DOI":"10.1074\/jbc.M414337200","article-title":"Functional Characterization of Novel Human and Mouse Equilibrative Nucleoside Transporters (hENT3 and mENT3) Located in Intracellular Membranes","volume":"280","author":"Baldwin","year":"2005","journal-title":"J. Biol. Chem."},{"key":"B3","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1161\/01.RES.0000238359.18495.42","article-title":"Distribution and Functional Characterization of Equilibrative Nucleoside Transporter-4, a Novel Cardiac Adenosine Transporter Activated at Acidic pH","volume":"99","author":"Barnes","year":"2006","journal-title":"Circ. Res."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.bmcl.2009.12.025","article-title":"Aryl- and Heteroaryl-Substituted Aminobenzo[a]quinolizines as Dipeptidyl Peptidase IV Inhibitors","volume":"20","author":"Boehringer","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B5","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/med.20221","article-title":"Transporters that Translocate Nucleosides and Structural Similar Drugs: Structural Requirements for Substrate Recognition","volume":"32","author":"Cano-Soldado","year":"2012","journal-title":"Med. Res. Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"5288","DOI":"10.1074\/jbc.273.9.5288","article-title":"Cloning of the Human Equilibrative, Nitrobenzylmercaptopurine Riboside (NBMPR)-Insensitive Nucleoside Transporter Ei by Functional Expression in a Transport-Deficient Cell Line","volume":"273","author":"Crawford","year":"1998","journal-title":"J. Biol. Chem."},{"key":"B7","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.tiv.2015.04.001","article-title":"Hepatotoxicity of Piperazine Designer Drugs: Comparison of Different In Vitro Models","volume":"29","author":"Dias-da-Silva","year":"2015","journal-title":"Toxicol. Vitro."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1096\/fj.13-228551","article-title":"Crosstalk between the Equilibrative Nucleoside Transporter ENT2 and Alveolar Adora2b Adenosine Receptors Dampens Acute Lung Injury","volume":"27","author":"Eckle","year":"2013","journal-title":"FASEB J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/s0223-5234(00)00167-7","article-title":"Hydrophobicity: Is LogP(o\/w) More Than the Sum of its Parts?","volume":"35","author":"Eugene Kellogg","year":"2000","journal-title":"Eur. J. Med. Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"G910","DOI":"10.1152\/ajpgi.90672.2008","article-title":"Facilitated Mitochondrial Import of Antiviral and Anticancer Nucleoside Drugs by Human Equilibrative Nucleoside Transporter-3","volume":"296","author":"Govindarajan","year":"2009","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1042\/bj3280739","article-title":"Molecular Cloning and Characterization of a Nitrobenzylthioinosine-Insensitive (Ei) Equilibrative Nucleoside Transporter from Human Placenta","author":"Griffiths","year":"1997","journal-title":"Biochem. J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"7726","DOI":"10.1016\/j.bmc.2007.08.058","article-title":"Novel C2-Purine Position Analogs of Nitrobenzylmercaptopurine Riboside as Human Equilibrative Nucleoside Transporter 1 Inhibitors","volume":"15","author":"Gupte","year":"2007","journal-title":"Bioorg. Med. Chem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1016\/j.bmcl.2004.02.016","article-title":"Novel Halogenated Nitrobenzylthioinosine Analogs as Es Nucleoside Transporter Inhibitors","volume":"14","author":"Gupte","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1124\/jpet.103.060434","article-title":"Interaction of the Novel Adenosine Uptake Inhibitor 3-[1-(6,7-Diethoxy-2-Morpholinoquinazolin-4-Yl)piperidin-4-Yl]-1,6-Dimethyl-2,4(1h,3h)-Quinazolinedione Hydrochloride (KF24345) with the Es and Ei Subtypes of Equilibrative Nucleoside Transporters","volume":"308","author":"Hammond","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s002100000214","article-title":"Interaction of a Series of Draflazine Analogues with Equilibrative Nucleoside Transporters: Species Differences and Transporter Subtype Selectivity","volume":"361","author":"Hammond","year":"2000","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"B16","first-page":"659","article-title":"Nitrobenzylthioinosine-sensitive Nucleoside Transport System: Mechanism of Inhibition by Dipyridamole","volume":"30","author":"Jarvis","year":"1986","journal-title":"Mol. Pharmacol."},{"key":"B17","first-page":"515","article-title":"Design, Synthesis, and Biological Evaluation of Indole-Based 1,4-disubstituted Piperazines as Cytotoxic Agents","volume":"36","author":"Koksal Akkoc","year":"2012","journal-title":"Turkish J. Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0005-2736(87)90091-5","article-title":"Purification and Reconstitution Studies of the Nucleoside Transporter from Pig Erythrocytes","volume":"904","author":"Kwong","year":"1987","journal-title":"Biochim. Biophys. Acta."},{"key":"B19","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.bcp.2005.05.010","article-title":"Effect of Thiazolidinediones on Equilibrative Nucleoside Transporter-1 in Human Aortic Smooth Muscle Cells","volume":"70","author":"Leung","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1517\/17425255.3.5.705","article-title":"The Role of Mitochondrial and Plasma Membrane Nucleoside Transporters in Drug Toxicity","volume":"3","author":"Leung","year":"2007","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1021\/jm070311l","article-title":"Synthesis, Flow Cytometric Evaluation, and Identification of Highly Potent Dipyridamole Analogues as Equilibrative Nucleoside Transporter 1 Inhibitors","volume":"50","author":"Lin","year":"2007","journal-title":"J. Med. Chem."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1016\/j.bbadis.2015.07.002","article-title":"Equilibrative Nucleoside Transporter 3 Depletion in \u03b2-cells Impairs Mitochondrial Function and Promotes Apoptosis: Relationship to Pigmented Hypertrichotic Dermatosis with Insulin-dependent Diabetes","volume":"1852","author":"Liu","year":"2015","journal-title":"Biochim. Biophys. Acta."},{"key":"B23","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/00005344-200009000-00011","article-title":"Inhibition of Adenosine Uptake and Augmentation of Ischemia-Induced Increase of Interstitial Adenosine by Cilostazol, an Agent to Treat Intermittent Claudication","volume":"36","author":"Liu","year":"2000","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2174\/157016109789043892","article-title":"Nucleoside Transporter Proteins","volume":"7","author":"Molina-Arcas","year":"2009","journal-title":"Curr. Vasc. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1021\/jm301782e","article-title":"Development of Dual PLD1\/2 and PLD2 Selective Inhibitors from a Common 1,3,8-Triazaspiro[4.5]decane Core: Discovery of Ml298 and Ml299 that Decrease Invasive Migration in U87-MG Glioblastoma Cells","volume":"56","author":"O'Reilly","year":"2013","journal-title":"J. Med. Chem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/0006-2952(93)90499-m","article-title":"Inhibitory Effects of Propentofylline on [3H]adenosine Influx. A Study of Three Nucleoside Transport Systems","volume":"46","author":"Parkinson","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/0304-3940(82)90368-8","article-title":"Benzodiazepines Are Weak Inhibitors of [3H]nitrobenzylthioinosine Binding to Adenosine Uptake Sites in Brain","volume":"29","author":"Patel","year":"1982","journal-title":"Neurosci. Lett."},{"key":"B28","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.1016\/j.bmcl.2014.10.026","article-title":"Dilazep Analogues for the Study of Equilibrative Nucleoside Transporters 1 and 2 (ENT1 and ENT2)","volume":"24","author":"Playa","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.chembiol.2012.07.016","article-title":"A Potent and Selective S1P(1) Antagonist with Efficacy in Experimental Autoimmune Encephalomyelitis","volume":"19","author":"Quancard","year":"2012","journal-title":"Chem. Biol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1177\/2472555219870123","article-title":"Current Progress on Equilibrative Nucleoside Transporter Function and Inhibitor Design","volume":"24","author":"Rehan","year":"2019","journal-title":"SLAS Discov."},{"key":"B31","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s40256-019-00345-5","article-title":"Adenosine and the Cardiovascular System","volume":"19","author":"Reiss","year":"2019","journal-title":"Am. J. Cardiovasc. Drugs."},{"key":"B32","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1097\/00000542-200002000-00041","article-title":"Midazolam Selectively Potentiates the A(2A) - but Not A1- Receptor-Mmediated Effects of Adenosine: Role of Nucleoside Transport Inhibition and Clinical Implications","volume":"92","author":"Seubert","year":"2000","journal-title":"Anesthesiology."},{"key":"B33","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1021\/jp015514e","article-title":"A View of the Hydrophobic Effect","volume":"106","author":"Southall","year":"2002","journal-title":"J. Phys. Chem. B."},{"key":"B34","doi-asserted-by":"publisher","first-page":"8146","DOI":"10.1021\/bi0101805","article-title":"Equilibrative Nucleoside Transporters: Mapping Regions of Interaction for the Substrate Analogue Nitrobenzylthioinosine (NBMPR) Using Rat Chimeric Proteins","volume":"40","author":"Sundaram","year":"2001","journal-title":"Biochemistry."},{"key":"B35","doi-asserted-by":"publisher","first-page":"21519","DOI":"10.1074\/jbc.273.34.21519","article-title":"Chimeric Constructs between Human and Rat Equilibrative Nucleoside Transporters (hENT1 and rENT1) Reveal hENT1 Structural Domains Interacting with Coronary Vasoactive Drugs","volume":"273","author":"Sundaram","year":"1998","journal-title":"J. Biol. Chem."},{"key":"B36","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.ejphar.2016.07.002","article-title":"Inhibition of Human Equilibrative Nucleoside Transporters by 4-((4-(2-Fluorophenyl)piperazin-1-Yl)methyl)-6-Imino-N-(naphthalen-2-Yl)-1,3,5-Triazin-2-Amine","volume":"791","author":"Tang","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"113747","DOI":"10.1016\/j.bcp.2019.113747","article-title":"Affinity, Binding Kinetics and Functional Characterization of Draflazine Analogues for Human Equilibrative Nucleoside Transporter 1 (SLC29A1)","volume":"172","author":"Vlachodimou","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"8375","DOI":"10.1074\/jbc.275.12.8375","article-title":"Kinetic and Pharmacological Properties of Cloned Human Equilibrative Nucleoside Transporters, ENT1 and ENT2, Stably Expressed in Nucleoside Transporter-Deficient PK15 Cells. Ent2 Exhibits a Low Affinity for Guanosine and Cytidine but a High Affinity for Inosine","volume":"275","author":"Ward","year":"2000","journal-title":"J. Biol. Chem."},{"key":"B39","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41594-019-0245-7","article-title":"Structures of Human ENT1 in Complex with Adenosine Reuptake Inhibitors","volume":"26","author":"Wright","year":"2019","journal-title":"Nat. Struct. Mol. Biol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.bbi.2019.11.008","article-title":"Deletion of Equilibrative Nucleoside Transporter-2 Protects against Lipopolysaccharide-Induced Neuroinflammation and Blood-Brain Barrier Dysfunction in Mice","volume":"84","author":"Wu","year":"2020","journal-title":"Brain Behav. Immun."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.837555\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T11:12:12Z","timestamp":1645441932000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.837555\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,21]]},"references-count":40,"alternative-id":["10.3389\/fphar.2022.837555"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.837555","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,21]]},"article-number":"837555"}}